Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey.

Ergun Oksuz Simten Malhan Mustafa Sait Gönen Zekayi Kutlubay Yilmaz KeskindemirciJames JarrettToros SahinGokcem OzcagliAhmet BilgicMerve Ozlem BibilikÖmer Fehmi Tabak

Published in: Advances in therapy (2021)

Remdesivir, which results in shorter LOS and lower rates of intubation requirements in ICU patients than existing therapies, is associated with higher QALYs and lower costs, dominating SoC in patients with SpO2 < 94% who require oxygen support.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
intensive care unit
sars cov
peritoneal dialysis
cardiac arrest
mechanical ventilation
patient reported outcomes
mesenchymal stem cells
patient reported